Formycon AG | Mutual Funds
Mutual Funds that own Formycon AG
170,000
1.87%
0
6.3%
03/31/2018
MOZART One
118,210
1.3%
28,882
5.21%
12/31/2017
PPF (PMG Partners Funds) - CP Global BioPharma Fund
56,000
0.62%
0
4.26%
05/31/2018
Adamant Global Generika
55,664
0.61%
0
2.71%
12/29/2017
Luxembourg Selection Fund - Xantos
38,666
0.43%
0
1.92%
01/31/2018
PEH Quintessenz SICAV - Q - Europa
17,000
0.19%
0
3.05%
07/31/2018
15,000
0.17%
0
2.06%
09/30/2017
Plutos - Multi Chance Fund
15,000
0.17%
15,000
2.73%
09/30/2017
Lux - Provest - Everest Nutrix
14,000
0.15%
14,000
2.33%
10/31/2017
HippokratAS
12,500
0.14%
2,500
0.55%
09/30/2017
| Address |
Fraunhoferstraße 15
Munich Bayern (Bavaria) 82152
Germany
|
|
Employees
|
- |
| Website |
http://formycon.com |
| Updated |
07/08/2019 |
| Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205 which focusoin the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany. |
